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Abstract. Pituitary metastases occur in 6-8% of breast 
cancer cases, but are seldom diagnosed and rarely reported. 
Therefore, it can be challenging to establish a clinical differ-
ential diagnosis, and at present, a definitive criteria is not 
available. The present study discusses the pituitary lesions 
identified in three patients with breast cancer, and describes 
their management within the collaborative framework of 
the Breast Unit at the Città della Salute Hospital, which 
also included assessment by endocrinologists. The patients 
were evaluated for anterior and posterior pituitary function, 
the appearance of the pituitary upon magnetic resonance 
imaging (MRI), and the oncology status and treatment. In 
addition, successive analysis of prolactin levels and the MRI 
was performed. The patients, aged 75, 83 and 76 years old, 
differed in their clinical presentation and successive evolu-
tion. One patient demonstrated an abrupt onset of diabetes 
insipidus, the second exhibited overt hypopituitarism and the 
final patient had a pituitary mass discovered by chance. Cases 
one and three exhibited systemic spread of the breast cancer, 
with bone and/or parenchymal metastasis, but not brain 
metastasis. Case two presented with a secondary pituitary 
tumour alone. In case three, a secondary nature to the pitui-
tary lesion was unlikely, since there was no lesion evolution 
evident following MRI and as stable prolactin levels were 
observed over the course of the study period. By contrast, 
case one presented with a rapid increase of sellar lesions 
on MRI, together with a progressive rise in prolactin levels. 
Taking into account the frailty of breast cancer patients who 
are monitored for disease progression, management in a 
collaborative framework, such as at the Breast Unit, makes 
it possible to establish a diagnosis of sellar lesions, which is 
adequate for the comprehensive management of the patient 
with successive pituitary MRIs and prolactin evaluations, 
and avoids unnecessary invasive neurosurgery.
Introduction
In breast cancer patients, the development of metastatic disease 
is considered to be the major cause of mortality (1). The inva-
sion‑metastasis cascade is a multistep process in which breast 
cancer cells invade the systemic circulation and distant tissues, 
and cause the metastatic colonization of different organs, 
including the bones, lungs and central nervous system (2). Being 
highly vascularized, the pituitary gland is a target structure for 
metastatic spread, accounting for 0.14-28% of all reported brain 
metastases following autopsy (3). In total, 6‑8% of breast cancer 
cases demonstrate metastatic spread to the pituitary gland (4). 
Despite this, pituitary metastases are seldom diagnosed and 
rarely described in surgical series, overall representing just 1% 
of surgically-resected tumours in the sellar region (5). The clin-
ical differential diagnosis of benign lesions in the sellar region 
is challenging, and at present, a definitive clinical criteria is not 
available (6). The majority of patients may be asymptomatic, but 
the most common symptoms include central diabetes insipidus, 
anterior hypopituitarism, visual loss and central nervous system 
disorders (7). Furthermore, the treatment of secondary pituitary 
lesions, for example with surgery, radiotherapy or chemotherapy, 
is far from being defined.
In the Città della Salute Hospital (Turin, Italy), breast 
cancer patients are referred to the Breast Unit, where surgeons, 
oncologists and other specialists have established a collabo-
rative framework. Recently, endocrinologists have also been 
included in the staff of the Breast Unit, from 75 patients 
referred to the endocrinologists between April 2012 to 
January 2014, three cases of sellar region lesions have been 
identified. The present study describes three cases of pituitary 
lesions in breast cancer patients who demonstrated different 
clinical presentations and histories, and discusses the correct 
diagnostic process and management. Patients provided written 
informed consent.
Case report
Case one. A 75‑year‑old female presented at the Breast Unit 
of the Città della Salute Hospital in September 2012 and was 
diagnosed with infiltrating ductal breast cancer [pathological 
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staging, PT1c pNx; oestrogen receptor (ER)- and proges-
terone receptor‑negative; Her2/neu, 80%) 12 years previously. 
Following left quadrectomy, the patient received chemotherapy 
(6 cycles, each cycle lasts 21 days) consisting of fluorouracil 
(600 mg/m2 on day 1), epirubicin (100 mg/m2 on day 1) and 
cyclophosphamide (600 mg/m2 on day 1), and underwent 
radiotherapy on the other breast. One year later, the patient 
presented with secondary axillary node lesions (pN2, node 
6/11) and received chemotherapy with taxotere (100 mg/m2 on 
days 1-14, 8 cycles, each cycle lasting 21 days). Subsequently, a 
further local recurrence, with pleural effusion, was identified, 
which required chemotherapy (8 cycles, each lasting 21 days) 
with vinorelbine (35 mg/m2 on days 1-8) and capecitabine 
(1,250 mg/m2 twice daily, on days 1‑14), which was adminis-
tered systemically. Following this, the patient began treatment 
with examestane (25 mg/day). Despite therapy, the disease 
progressed with bone dissemination, which was treated with 
zolendronate. At the end of 2011, the patient complained of 
polydipsia, with a water intake of ~3 litres in 24 h, and poly-
uria, particularly at night, with diuresis of ~5 litres every 24 h. 
The laboratory data revealed a low urine density (normal, 
1005-1028 g/cm3), a high serum sodium concentration 
(147 mmol/l; normal, 135‑145 mmol/l) and a slight increase 
in prolactin levels (30.4 ng/ml). Normal ranges are shown in 
Table I. The fasting blood glucose (normal, 70-109 mg/dl) and 
anterior pituitary hormone levels were in the normal range. 
MRI revealed an increase in the size of the pineal and pituitary 
glands, which was characterized by a heterogeneous T2 signal 
and by contrast enhancement. The pituitary stalk was enlarged 
and demonstrated strong enhancement when using gadolinium 
contrast medium. The patient was treated with 60 mg/day oral 
desmopressin, and demonstrated a good initial response, with 
the serum sodium level decreasing to 141 mmol/l and diuresis 
to ~50%. After three months, the prolactin levels were signifi-
cantly elevated and reached 141 ng/ml, without any further 
worsening of the diuresis pattern or any visual defects. The 
MRI scan was repeated and revealed a clear progression of 
the pineal-pituitary lesion, with an increased involvement 
of the stalk and optic chiasms. The patient was considered 
eligible for stereotactic radiotherapy (STR) of the sellar region, 
however, shortly after, the general and respiratory condition 
deteriorated and the patient succumbed to the disease.
The hormone levels and MRI results are presented in 
Table I and Fig. 1A, respectively.
Case two. An 83‑year‑old female was admitted to the Emer-
gency Department of the Città della Salute Hospital in early 
2012 with symptoms of weakness, weight loss, hypotension 
and recurrent dizziness. A physical examination revealed 
the presence of a palpable, hard and irregular mass in the 
right breast. The patient had not sought any previous medical 
advice, but reported that the mass had been apparent for 
approximately two years. Following pituitary function evalu-
ation, reduced levels of morning serum cortisol, free‑urinary 
cortisol, adrenocorticotropic hormone, free triiodothyronine 
(fT3), free thyroxine (fT4), thyroid‑stimulating hormone 
(TSH), luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) were observed. By contrast, prolactin 
serum levels were increased (152 ng/dl). Following the 
start of hormone replacement therapy with hydrocortisone 
(20 mg/day) and L-thyroxin (75 µg/day), the patient under-
went a pituitary MRI, which revealed a large lesion with 
sovra‑sellar extension, optic chiasm infiltration and high 
post‑gadolinium enhancement. The visual field examination 
revealed the presence of a temporal right superior quadran-
tanopsia, despite the absence of overt visual disturbances. 
Therefore, the patient underwent trans‑sphenoidal surgery. 
The pituitary lesion was removed and upon histological 
examination, was diagnosed as a metastasis of mucinous 
breast cancer. A ultrasound‑guided percutaneous fine‑needle 
aspiration biopsy was performed upon the breast node, which 
established a positive result for infiltrating low‑grade carci-
noma with mucinous characteristics. No secondary lesions, 
other than the pituitary metastasis, were observed. No breast 
surgery was performed, however, treatment with anastrazole 
(1 mg/day) was initiated. The one‑year follow‑up examina-
tion revealed no evidence of disease progression. The patient 
was subsequently lost to follow‑up.
The hormone levels and MRI results are presented in 
Table I and Fig 1B, respectively.
Case three. A 76‑year‑old female was referred to the Breast 
Unit of the Città della Salute Hospital in April 2012 following 
evidence of a sellar lesion with a polylobulate aspect, 
measuring ~20 mm, upon brain MRI. The mass demonstrated 
high signal intensity upon T1‑weighted images, (suggesting 
lipid presence), and low signal intensity upon T2‑weighted 
images, with sovra‑sellar extension and pituitary involvement.
In 1997, the patient was diagnosed with breast cancer 
and underwent breast conservative treatment, consisting of 
a quadrantectomy and radiotherapy of the right breast. The 
histological examination established a diagnosis of ER- and 
cErb2‑positive ductal infiltrating breast cancer. The patient 
subsequently received adjuvant chemotherapy [epirubicin 
(120 mg/m2, once a week for 3 cycles)] and radiotherapy to 
the other breast. Evidence of recurrence was not observed 
until 2004, when the patient underwent chemotherapy 
[cyclophosphamide (100 mg, twice a day, on days 1‑14), 
methotrexate (40 mg/m2 on days 1-8) and f luorouracil 
(600 mg/m2 on days 1‑8), every 28 days, total of 6 cycles] and 
surgery, which consisted of a right mastectomy and a lymphad-
enectomy for the removal of nodal metastases in the right 
axilla. Subsequently, treatment with anastrazole (1 mg/day) 
was initiated. Disease progression was not observed until 
January 2010, when liver and bone metastases were identified. 
The patient was therefore treated with chemotherapy (3 cycles, 
each lasting 21 days), consisting of vinorelbine (35 mg/m2 on 
days 1-8) and capecitabine (1,250 mg/m2, twice a day on days 
1‑14), which lead to regression of the liver and bone lesions. 
In early 2011, a brain CT scan and MRI revealed only the 
presence of the aforementioned pituitary lesion. The pituitary 
function results revealed low levels of fT3, fT4 and TSH, 
extremely low levels of FSH and LH and a moderate increase 
in the level of prolactin (72 ng/ml). The adrenal function was 
normal, and no clinical or laboratory findings suggestive 
of diabetes insipidus were revealed. Hormone replacement 
therapy with L‑thyroxine (100 µg/day) was administered. 
Alterations in the visual field were not observed.
An MRI scan of the pituitary region repeated six months 
later did not reveal a significant difference in the mass 
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characteristics. The prolactin levels were also monitored 
every three months, and demonstrated no significant modi-
fications with respect to the basal level. The clinical and 
radiological features of the pituitary mass were suggestive 
of a craniopharyngioma, however, taking into account the 
oncology history and prognosis, and also the stability of the 
neurological symptoms, surgical treatment was excluded. The 
MRI results and prolactin levels remained stable one year after 
Figure 1. Magnetic resonance imaging (MRI) revealing the pituitary lesions. (A) MRI from case one. Left, at the time of diagnosis, and right, six months later. 
(B) MRI from case two. Left and right images taken prior to the trans‑sphenoidal surgery. (C) MRI from case three. Left, at the time of diagnosis, and right, 
six months later. Arrows indicate lesion sites.
Table I. Hormone assays at the time of pituitary mass diagnosis.
Hormone assay Case one Case two Case three Normal
ACTH (pg/ml) 12.0 8.0 36.0 <46.0
Morning cortisol (µg/dl) 20.7 1.0 10.2 6.2-19.4
Prolactin (ng/ml) 35.5 152.5 72.8 4.8‑23.3
TSH (µIU/ml) 2.2 2.0 0.8 0.37‑4.2
fT4 (pg/ml) 11.5 5.4 7.0 9.3‑17.0
fT3 (pg/ml) 3.2 1.4 3.3 2.6‑4.4
FSH (mIU/ml) 88.4 0.5 6.3 a
LH (mIU/ml) 38.0 <0.1 1.2 b
IGF1 (ng/ml) 121.0 59.0 72.7 110‑385
p‑Osmolality (mOsm/kg) 294.0 297.0 290.0 
u‑Osmolality (mOsm/kg) 156.0 622.0 562.0 
aNormal range: FSH (follicular phase), 3.5‑12.5 mUI/l; FSH (luteal phase), 1.7‑17.7 mUI/l; FSH (menopause), 5.8‑134.8 mUI/l. bNormal 
range: LH (follicular phase), 2.4‑12.6 mUI/l; LH (luteal phase), 1.0‑11.4 mUI/l; LH (menopause), 7.7‑58.5 mUI/l. ACTH, adrenocorticotropic 
hormone; TSH, thyroid‑stimulating hormones; fT4, free thryoxine; fT3, free triiodothyronine; FSH, follicle‑stimulating hormone; LH, lutein-
izing hormone; IGF1, insulin‑like growth factor‑1; p, plasma; u, urine.
  A
  B
  C
FORTUNATI et al:  PITUITARY LESIONS AND BREAST CANCER 2765
the diagnosis of the pituitary lesion. While the pituitary mass 
did not increase in size, further progression of the secondary 
liver lesions was observed, and therefore the patient continues 
to receive chemotherapy. 
The hormone levels and MRI are presented in Table I and 
in Fig. 1C, respectively.
Discussion
Since the first reported case of a pituitary metastasis by 
Benjamin (8) in 1857, the number of recorded cases has 
increased over time. At present, it is reported that following 
autopsy, pituitary lesions account for 0.14-28.1% of all brain 
metastases (3,6,9). Despite this, clinical detection and manage-
ment of the lesions remain complex and ambiguous.
The current literature regarding pituitary metastases 
generally describes lesions discovered by neurosurgeons or 
endocrinologists. The present study reports an integrated 
management of breast cancer patients at the Breast Unit at 
the Città della Salute Hospital, where oncologists and endo-
crinologist work together. The present study therefore aimed 
to delineate how to diagnose a breast cancer patient when 
the suspicion of a pituitary lesion arises. Between April 2012 
and January 2014, 75 breast cancer patients, who had been 
referred to the Endocrinology Service of the Breast Unit, were 
considered for use in the present study. Of these, three patients, 
who represented 4% of the total population, presented with a 
pituitary mass.
It is recognized that pituitary metastasis usually affects 
elderly patients in the sixth or seventh decades of life (10). 
Furthermore, pituitary metastases, which are more often 
observed in breast and lung cancer patients, are usually part 
of a systemic spread, and are frequently associated with bone 
localization (7). The patients included in the present study 
were older than 70 years, which suggests that age is an impor-
tant factor to be considered. With regard to pituitary lesions 
and their association with disease progression and systemic 
spread, in the present study, it was true only in case one. In 
case two, the pituitary metastasis was the first and only sign of 
breast cancer spread, and in case three, where the exact nature 
of the lesions was unknown (craniopharyngioma was clini-
cally diagnosed), the breast cancer progression was observed 
later without any modification of the pituitary lesion.
The clinical presentation of a sellar lesion is believed to 
be suggestive of a pituitary metastasis when it is character-
ized by the abrupt appearance of diabetes insipidus (3,7). This 
presentation has been associated with a poor prognosis within 
one year of a diabetes insipidus diagnosis. Metastatic spread 
is more common to the pituitary posterior lobe, mainly due 
to the particular anatomy of the supplying arteries. While the 
anterior lobe lacks a direct arterial blood supply, the poste-
rior lobe is directly supplied by the hypophyseal arteries (7). 
Therefore, the involvement of the anterior lobe is believed to 
be a result of contiguous spread from the posterior lobe. Previ-
ously, it was reported that diabetes insipidus occurred in 70% 
of symptomatic cases of pituitary metastasis, and that anterior 
pituitary deficiency was identified in 15% of those patients (7). 
In the present study, pituitary metastasis was diagnosed in 
case one following symptoms of diabetes insipidus, and was 
subsequently associated with a poor prognosis. In case three, 
where the pituitary lesion was found not to be malignant, an 
anterior pituitary partial deficiency, which was limited to 
thyroid function, was observed. Case two presented with overt 
hypopituitarism and a well‑demonstrated deficiency in adrenal 
and thyroid function.
The symptoms of diabetes insipidus in a patient with meta-
static breast cancer may suggest the presence of a pituitary 
metastasis (11), and therefore should prompt a pituitary MRI 
scan. However, it should be noted that the absence of diabetes 
insipidus should not completely dismiss the potential occur-
rence of hypophyseal spread.
The patients in the present study did not present with visual 
disturbances, headaches or ophthalmoplegia, however, this 
was not of much use during the differential diagnosis, as such 
symptoms are frequently observed in patients with pituitary 
adenomas (11).
The final endocrine aspect to be discussed is the level of 
prolactin at diagnosis and its behaviour. A previous study 
reported that hyperprolactinaemia is present in 6.3% of pitui-
tary metastases, and that levels >200 ng/ml are suggestive of 
a prolactinoma (7). Mean prolactin levels in cases of pituitary 
metastasis are ~150 ng/ml and are believed to result from stalk 
compression (12). In agreement with this, none of the patients 
in the present study demonstrated prolactin levels >200 ng/ml, 
but the two with pituitary metastases did exhibit high prol-
actin levels of ~150 ng/ml on at least one occasion during the 
study. The opportunity to follow‑up patients during the months 
following the diagnoses allowed for notable observations to 
be made (Fig. 2). The change in prolactin levels over time 
could be suggestive of the evolution of the lesion. Only case 
three presented with moderately elevated prolactin levels, but 
these remained stable over time. In the other patients, prolactin 
was >100 ng/ml at diagnosis, or increased above this value as 
the lesion progressed. Therefore, this last observation should 
be taken into consideration. When possible, prolactin levels 
should be monitored over time, with increases suggesting the 
potential presence of an evolving pituitary mass. This was 
confirmed in case one by MRI, which demonstrated a clear 
increase in the size of the pituitary lesion, and the presence of 
stalk involvement over time. In case three, the lesion remained 
stable on MRI, as did the prolactin levels, despite breast 
disease progression. Furthermore, since none of the patients 
Figure 2. Prolactin levels evaluated in the three patients at the time of pituitary 
lesion diagnosis, and at three and six months later. TNS, trans-sphenoidal.
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took anti‑dopaminergic agents during the endocrinological 
assessment, the prolactin levels have to be considered as a 
reliable hormonal marker. Therefore, it can be suggested that 
in breast cancer patients with a suspected pituitary metastasis, 
an evaluation of prolactin levels and an MRI scan at different 
time intervals may aid in the differential diagnosis.
The only approach able to provide a definite diagnosis is 
a biopsy of the sellar lesion, which requires trans‑sphenoidal 
surgery performed by an experienced neurosurgical team. 
Previously, it has been reported that surgery, despite providing 
pathological confirmation of the disease, does not increase the 
mean survival time (5,6) of 6‑7 months (9), but does improve 
quality of life. Therefore, surgery should be performed in 
patients who have experienced a consistent reduction in the 
quality of their life (5) or in order to decompress the optic 
nerves and chiasm (13). A surgical approach to obtain a histo-
logical diagnosis is advisable when the primary site of the 
tumour is unknown. At the Breast Unit, MRI and prolactin 
evaluation at different time‑points (e.g., intervals of one to 
three months), together with a pituitary functional assessment 
at the first observation, are currently performed and should 
provide a clinician with the correct interpretation of the 
biological behaviour of the sellar lesion. Finally, an exhaus-
tive evaluation of patient quality of life, life expectancy and 
surgical risk has to be performed in each case in order to make 
an informed decision regarding surgery.
As suggested by previous studies, when overt symptoms, 
such as visual disturbances and headaches, or a marked 
increase in the size of the lesion over a short period of time 
requires treatment, but surgery cannot be considered, an 
attractive and effective therapeutic option is radiation therapy, 
either traditional or sterotactic (5,14). STR was suggested for 
one of the patients in the present study, but disease spread 
with critical clinical deterioration did not allow for any 
further treatment.
Despite no published literature existing on the potential 
molecular pathways involved in breast cancer cell spread to 
the pituitary gland, certain putative candidates appear note-
worthy, particularly pituitary tumour‑transforming gene 1 
(PTTG1) (15). PTTG1 is a pituitary‑derived transforming 
gene, and its cognate protein, PTTG1, exhibits a high-grade 
homology to securin, which in vertebrates regulates sister chro-
matid separation during mitosis (15). Furthermore, PTTG1 has 
been reported to be overexpressed in several hormone‑related 
tumours, such as pituitary, thyroid, breast, ovarian and uterine 
cancers. In addition, PTTG1 is associated with tumour metas-
tasis and its expression in breast cancer has been proposed to 
be a marker of aggressiveness. Despite being only speculative, 
PTTG1 may be involved in the spread of breast cancer to the 
pituitary, and therefore requires future investigation.
In conclusion, the present study reported three cases of 
breast cancer with corresponding pituitary masses. Of the 
three cases, one behaved as a benign lesion and demonstrated 
characteristics of a craniopharyngioma, while the other 
two were secondary lesions of the primitive neoplasm. It 
is suggested that when breast cancer patients are managed 
within a collaborative framework, such as the Breast Unit at 
the Città della Salute Hospital, it is possible to establish an 
adequate diagnosis of sellar lesions and avoid unnecessary 
invasive neurosurgery, which is favourable when considering 
the frailty of these patients. Repeated pituitary MRI and prol-
actin evaluation following a correct pituitary function study 
may be useful tools for making a therapeutic decision. Finally, 
the present study suggests a valuable role for endocrinologists 
during the diagnosis and treatment of breast cancer patients.
Acknowledgements
The authors would like to thank Dr Dino Daniele and 
Dr Mauro Bergui (Neuroradiology Unit) for providing assis-
tance with the MRI scans.
References
 1. Gupta GP and Massagué J: Cancer metastasis: building a 
framework. Cell 127: 679‑695, 2006.
 2. Nguyen DX, Bos PD and Massagué J: Metastasis: from dissemi-
nation to organ‑specific colonization. Nat Rev Cancer 9: 274‑284, 
2009.
 3. Sioutos P, Yen V and Arbit E: Pituitary gland metastases. Ann 
Surg Oncol 3: 94‑99, 1996.
 4. Fassett DR and Couldwell WT: Metastases to the pituitary gland. 
Neurosurg Focus 16: E8, 2004.
 5. Zoli M, Mazzatenta D, Faustini-Fustini M, Pasquini E 
and Frank G: Pituitary metastases: role of surgery. World 
Neurosurg 79: 327‑330, 2013.
 6. Marsh JC, Garg S, Wendt JA, Gielda BT, Turian JV and 
Herskovic AM: Intracranial metastatic disease rarely involves 
the pituitary: retrospective analysis of 935 metastases in 155 
patients and review of the literature. Pituitary 13: 260‑265, 2010.
 7. Komninos J, Vlassopoulou V, Protopapa D, Korfias S, 
Kontogeorgos G, Sakas DE and Thalassinos NC: Tumors meta-
static to the pituitary gland: case report and literature review. 
J Clin Endocrinol Metab 89: 574-80, 2004. 
 8. Benjamin L: Ein Krebsfall. Virchows Arch Path Anat 12: 
566-569, 1857
 9. Chiang MF, Brock M and Patt S: Pituitary metastasis. 
Neurochirurgia (Stuttg) 33: 127‑131, 1990.
10. Freda PU and Post KD: Differential diagnosis of sellar masses. 
Endocrinol Metab Clin North Am 28: 81‑117, 1999.
11. Shubinger O and Haller D: Metastases to the pituitary - hypo-
thalamic axis. An MR study of 7 symptomatic patients. 
Neuroradiology 34: 131‑134, 1992.
12. Leramo OB, Booth JD, Zinman B, Bergeron C, Sima AA 
and Morley TP: Hyperprolactinemia, hypopituitarism, and 
chiasmal compression due to carcinoma metastatic to the 
pituitary. Neurosurgery 8: 477-480, 1981.
13. Post KD: Pituitary metastases: what is the role of surgery? 
World Neurosurg 79: 251‑252, 2013.
14. Turaka A, Parsons RB and Buyyounouski MK: Radiation 
therapy for pituitary metastasis: report of four cases. 
Tumori 98: e1-e6, 2012.
15. Vlotides G, Eigler T and Melmed S: Pituitary tumor‑trans-
forming gene: physiology and implications for tumorigenesis. 
Endocr Rev 28: 165‑186, 2007.
